HB0045 Drug Product Clinical Trials

1 actively recruiting trial across 1 location

Also known as: fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73

Filter by location:

Boston, Massachusetts1 trial

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.